Show simple item record

dc.contributor.authorSoni, Apurv
dc.contributor.authorHerbert, Carly
dc.contributor.authorFilippaios, Andreas
dc.contributor.authorBroach, John P.
dc.contributor.authorColubri, Andres
dc.contributor.authorFahey, Nisha
dc.contributor.authorWoods, Kelsey
dc.contributor.authorNanavati, Janvi
dc.contributor.authorWright, Colton
dc.contributor.authorOrwig, Taylor
dc.contributor.authorGilliam, Karen
dc.contributor.authorLin, Honghuang
dc.contributor.authorO'Connor, Laurel
dc.contributor.authorPretz, Caitlin
dc.contributor.authorAyturk, M. Didem
dc.contributor.authorOrvek, Elizabeth Aaker
dc.contributor.authorFlahive, Julie M.
dc.contributor.authorLazar, Peter
dc.contributor.authorShi, Qiming
dc.contributor.authorGibson, Laura L.
dc.contributor.authorStamegna, Pamela
dc.contributor.authorHafer, Nathaniel
dc.contributor.authorLuzuriaga, Katherine
dc.contributor.authorBarton, Bruce A.
dc.contributor.authorMcManus, David D.
dc.contributor.authorRADx Clinical Studies Core team and Test Us At Home Investigators
dc.date2022-08-11T08:08:34.000
dc.date.accessioned2022-08-23T15:59:44Z
dc.date.available2022-08-23T15:59:44Z
dc.date.issued2022-03-02
dc.date.submitted2022-06-01
dc.identifier.citation<p>Soni A, Herbert C, Filippaios A, Broach J, Colubri A, Fahey N, Woods K, Nanavati J, Wright C, Orwig T, Gilliam K, Kheterpal V, Suvarna T, Nowak C, Schrader S, Lin H, O'Connor L, Pretz C, Ayturk D, Orvek E, Flahive J, Lazar P, Shi Q, Achenbach C, Murphy R, Robinson M, Gibson L, Stamegna P, Hafer N, Luzuriaga K, Barton B, Heetderks W, Manabe YC, McManus D. Comparison of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study. medRxiv [Preprint]. 2022 Mar 2:2022.02.27.22271090. doi: 10.1101/2022.02.27.22271090. PMID: 35262091; PMCID: PMC8902878. <a href="https://doi.org/10.1101/2022.02.27.22271090" target="_blank" title="view preprintin medrxiv">Link to preprint on medRxiv.</a></p>
dc.identifier.doi10.1101/2022.02.27.22271090
dc.identifier.pmid35262091
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30738
dc.description<p>This article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.</p> <p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractBackground: There is a need to understand the performance of rapid antigen tests (Ag-RDT) for detection of the Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) SARS-CoV-2 variants. Methods: Participants without any symptoms were enrolled from October 18, 2021 to January 24, 2022 and performed Ag-RDT and RT-PCR tests every 48 hours for 15 days. This study represents a non-pre-specified analysis in which we sought to determine if sensitivity of Ag-RDT differed in participants with Delta compared to Omicron variant. Participants who were positive on RT-PCR on the first day of the testing period were excluded. Delta and Omicron variants were defined based on sequencing and date of first RT-PCR positive result (RT-PCR+). Comparison of Ag-RDT performance between the variants was based on sensitivity, defined as proportion of participants with Ag-RDT+ results in relation to their first RT-PCR+ result, for different duration of testing with rapid Ag-RDT. Subsample analysis was performed based on the result of participants' second RT-PCR test within 48 hours of the first RT-PCR+ test. Results: From the 7,349 participants enrolled in the parent study, 5,506 met the eligibility criteria for this analysis. A total of 153 participants were RT-PCR+ (61 Delta, 92 Omicron); among this group, 36 (23.5%) tested Ag-RDT+ on the same day, and 84 (54.9%) tested Ag-RDT+ within 48 hours as first RT-PCR+. The differences in sensitivity between variants were not statistically significant (same-day: Delta 16.4% [95% CI: 8.2-28.1] vs Omicron 28.2% [95% CI: 19.4-38.6]; and 48-hours: Delta 45.9% [33.1-59.2] vs. Omicron 60.9% [50.1-70.9]). This trend continued among the 86 participants who had consecutive RT-PCR+ result (48-hour sensitivity: Delta 79.3% [60.3-92.1] vs. Omicron: 89.5% [78.5-96.0]). Conversely, the 38 participants who had an isolated RT-PCR+ remained consistently negative on Ag-RDT, regardless of the variant. Conclusions: The performance of Ag-RDT is not inferior among individuals infected with the SARS-CoV-2 Omicron variant as compared to the Delta variant. The improvement in sensitivity of Ag-RDT noted with serial testing is consistent between Delta and Omicron variant. Performance of Ag-RDT varies based on duration of RT-PCR+ results and more studies are needed to understand the clinical and public health significance of individuals who are RT-PCR+ for less than 48 hours.
dc.language.isoen_US
dc.relation<p><a href="https://pubmed.ncbi.nlm.nih.gov/35262091/" target="_blank" title="view preprint in PubMed">View preprint in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1101/2022.02.27.22271090
dc.rightsThe copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
dc.subjectInfectious Diseases
dc.subjectrapid antigen tests
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectUMCCTS funding
dc.subjectEpidemiology
dc.subjectImmunology and Infectious Disease
dc.subjectInfectious Disease
dc.subjectMicrobiology
dc.subjectVirus Diseases
dc.titleComparison of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study [preprint]
dc.typePreprint
dc.source.journaltitlemedRxiv
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/2209
dc.identifier.contextkey29483044
html.description.abstract<p><strong>Background: </strong>There is a need to understand the performance of rapid antigen tests (Ag-RDT) for detection of the Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) SARS-CoV-2 variants.</p> <p><strong>Methods: </strong>Participants without any symptoms were enrolled from October 18, 2021 to January 24, 2022 and performed Ag-RDT and RT-PCR tests every 48 hours for 15 days. This study represents a non-pre-specified analysis in which we sought to determine if sensitivity of Ag-RDT differed in participants with Delta compared to Omicron variant. Participants who were positive on RT-PCR on the first day of the testing period were excluded. Delta and Omicron variants were defined based on sequencing and date of first RT-PCR positive result (RT-PCR+). Comparison of Ag-RDT performance between the variants was based on sensitivity, defined as proportion of participants with Ag-RDT+ results in relation to their first RT-PCR+ result, for different duration of testing with rapid Ag-RDT. Subsample analysis was performed based on the result of participants' second RT-PCR test within 48 hours of the first RT-PCR+ test.</p> <p><strong>Results: </strong>From the 7,349 participants enrolled in the parent study, 5,506 met the eligibility criteria for this analysis. A total of 153 participants were RT-PCR+ (61 Delta, 92 Omicron); among this group, 36 (23.5%) tested Ag-RDT+ on the same day, and 84 (54.9%) tested Ag-RDT+ within 48 hours as first RT-PCR+. The differences in sensitivity between variants were not statistically significant (same-day: Delta 16.4% [95% CI: 8.2-28.1] vs Omicron 28.2% [95% CI: 19.4-38.6]; and 48-hours: Delta 45.9% [33.1-59.2] vs. Omicron 60.9% [50.1-70.9]). This trend continued among the 86 participants who had consecutive RT-PCR+ result (48-hour sensitivity: Delta 79.3% [60.3-92.1] vs. Omicron: 89.5% [78.5-96.0]). Conversely, the 38 participants who had an isolated RT-PCR+ remained consistently negative on Ag-RDT, regardless of the variant.</p> <p><strong>Conclusions: </strong>The performance of Ag-RDT is not inferior among individuals infected with the SARS-CoV-2 Omicron variant as compared to the Delta variant. The improvement in sensitivity of Ag-RDT noted with serial testing is consistent between Delta and Omicron variant. Performance of Ag-RDT varies based on duration of RT-PCR+ results and more studies are needed to understand the clinical and public health significance of individuals who are RT-PCR+ for less than 48 hours.</p>
dc.identifier.submissionpathfaculty_pubs/2209
dc.contributor.departmentDivision of Cardiovascular Medicine, Department of Medicine
dc.contributor.departmentDivision of Infectious Diseases and Immunology, Program in Molecular Medicine
dc.contributor.departmentUMass Center for Clinical and Translational Science
dc.contributor.departmentDepartment of Pediatrics
dc.contributor.departmentProgram in Bioinformatics and Integrative Biology
dc.contributor.departmentDepartment of Microbiology and Physiological Systems
dc.contributor.departmentDepartment of Emergency Medicine
dc.contributor.departmentDivision of Clinical Informatics, Department of Medicine
dc.contributor.departmentDepartment of Population and Quantitative Health Sciences
dc.contributor.departmentProgram in Digital Medicine, Department of Medicine


This item appears in the following Collection(s)

Show simple item record